A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Chimeric antigen receptor (CAR)-T cells reprogram the T cells to target tumor cells and have undergone several generations of enhancement. Accumulating evidence shows that by incorporating co-stimulatory molecules and single-chain variable fragments (scFvs), CAR-T cells maintain sustainable proliferation capacity along with high sensitivity and enhanced cytokines production. Moreover, CAR-T cell therapy has shown great promise in clinical trials. However, complications and toxicities must bedoi:10.21037/tcr.2018.06.11 fatcat:k3k5n3dvwbcghivn6tl5mdrqii